DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the CAR-T Therapy Pipeline Report
- DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
- The leading companies working in the CAR-T Therapy Market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
- Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
- December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
- December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
- November 2023: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd announced a study of Phase 1 clinical trials for CD19 CAR-T cells. This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
- November 2023: Chongqing Precision Biotech Co., Ltd announced a study of Phase 1 clinical trials for CEA CAR-T cells. This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignant tumors.
Request a sample and discover the recent advances in CAR-T Therapy Treatment Drugs @ CAR-T Therapy Pipeline Report
In the CAR-T Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
CAR-T Therapy Overview
Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.
Find out more about CAR-T Therapy Treatment Drugs @ Drugs for CAR-T Therapy Treatment
CAR-T Therapy Emerging Drugs Profile
- CT053: Carsgen Therapeutics
- Descartes-08: Cartesian Therapeutics
- ALLO-501A: Allogene Therapeutics
- CTX110: CRISPR Therapeutics
- IMPT 314: ImmPACT Bio
- ALLO-715: Allogene Therapeutics
CAR-T Therapy Pipeline Therapeutics Assessment
There are approx. 200+ key companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.
DelveInsight’s CAR-T Therapy pipeline report covers around 252+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
CAR-T Therapy Pipeline Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging CAR-T Therapy Pipeline Therapies @ CAR-T Therapy Clinical Trials Assessment
Scope of the CAR-T Therapy Pipeline Report
- Coverage- Global
- CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
- CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
Dive deep into rich insights for new drugs for CAR-T Therapy treatment, Visit @ CAR-T Therapy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- CAR-T Therapy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- CAR-T Therapy– DelveInsight’s Analytical Perspective
- Late Stage Products (Registered)
- CT053: Carsgen Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Descartes-08: Cartesian Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ALLO-715: Allogene Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- ACLX 003: Arcellx
- Drug profiles in the detailed report…..
- Inactive Products
- CAR-T Therapy Key Companies
- CAR-T Therapy Key Products
- CAR-T Therapy- Unmet Needs
- CAR-T Therapy- Market Drivers and Barriers
- CAR-T Therapy- Future Perspectives and Conclusion
- CAR-T Therapy Analyst Views
- CAR-T Therapy Key Companies
- Appendix
For further information on the CAR-T Therapy pipeline therapeutics, reach out @ CAR-T Therapy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fabry-disease-market